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SYMPTOMS EXPERIENCED BY POST-MENOPAUSAL BREAST CANCER 
SURVIVORS ON AROMATASE INHIBITORS: A SECONDARY ANALYSIS OF 
BASELINE DATA    
 
Background: Endocrine therapy for breast cancer with Aromatase Inhibitors (AI) is 
designed to reduce risk of recurrence and improve survival. AI therapy is associated with 
a variety of symptoms including musculoskeletal complaints, which have contributed to 
discontinuation of treatment. It is significantly important to explore the symptom profile 
of AIs that contribute to patients’ quality of life and adherence behavior. Objective: The 
purpose of the study was a secondary analysis exploring the symptom profile of post-
menopausal breast cancer survivors on AIs. Methods: Data were collected from self-
reported demographic and medical forms from 36 women on AIs identified in the 
primary study. Symptoms were identified using the Breast Cancer Prevention Trial 
Symptom Checklist (BCPT-SCL) and mean severity distress scores were calculated for 
each symptom. Results: The most frequently reported symptoms were musculoskeletal 
and vasomotor specifically joint pain (75%), hot flashes (75%), general aches and pains 
(75%), and muscle stiffness (69.4%). The highest reported mean severity distress score 
was unhappiness with body image. Conclusions: There is no confirmed etiology or 
established evidence based management for musculoskeletal complaints related to AI use. 
Future studies are needed to further understand AI-related musculoskeletal symptoms in 
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Statement of the Problem 
Women with post-menopausal breast cancer often undergo adjuvant endocrine 
therapy for hormone-responsive breast cancer.  Aromatase inhibitors (AI) have become 
an alternative to Tamoxifen for women with estrogen receptor positive (ER+) breast 
cancer to decrease breast cancer recurrence.  ER+ breast cancer grows in response to the 
hormone estrogen, and in post-menopausal women estrogen production happens in the 
peripheral tissues controlled by the enzyme aromatase that converts androgens into 
estrogens (Crew et. al, 2007).  The AI targeted therapy blocks this conversion, which in 
turn causes estrogen depletion in the body. 
However, AI therapy has a symptom profile that may decrease quality of life.  
Adverse symptoms include hot flashes, night sweats, musculoskeletal joint pain, fatigue, 
and bone loss (Freedman & Winer, 2010).  The higher prevalence and incidences of these 
adverse symptoms in patients undergoing AI therapy may be related to the efficacy of 
AIs decreasing estrogen concentration (Dent et. al, 2011).  The treatment-related adverse 
effects may jeopardize the reported disease free survival benefit due to adherence to AI 
therapy.  
The purpose of the study was a secondary analysis exploring the symptom profile 
of post-menopausal breast cancer survivors on aromatase inhibitors at baseline prior to 
participating in a 12-month randomized control trial comparing supervised aerobic-
resistance exercise to a home based control group.  Identifying the critical symptoms 
responsible for decreasing quality of life in breast cancer survivors on AI therapy will 
help improve the clinical decision-making model to maximize symptom management and 




minimize symptom occurrence.  These data may provide insight into the AI symptom 
profile and explore the severity associated with symptom presentation in post-
menopausal breast cancer survivors on AI adjuvant therapy.   
CHAPTER II 
Review of the Literature 
For post-menopausal breast cancer women undergoing adjuvant endocrine 
therapy, Tamoxifen and AIs have showed a marked reduction in breast cancer morbidity 
and mortality (Cigler & Gross, 2007). There have been recent findings that AIs may even 
be more effective at lowering recurrence rates compared to Tamoxifen (Dowsett et al., 
2010). With established disease-free benefits, it is of significant importance to explore the 
symptom toxicities of AIs that may lower patients’ quality of life and adherence behavior.  
 AI Symptom Profile. Aromatase inhibitors are an integral part of standard 
adjuvant hormone therapy for estrogen receptor-positive breast cancer that is generally 
well tolerated in patients. However, there have been certain symptoms that self-
reportedly lower quality of life in patients undergoing this particular therapy. Table 1, 
identifies the symptoms that are associated with AI treatment. Common side effects 
include musculoskeletal symptoms, changes in cognitive function, vasomotor and 
atrophic vaginal symptoms and loss of bone mass (Dent et al., 2011). A 6-month cohort 
study of 100 breast cancer patients initiating AI treatment (compared to a healthy cancer-
free control group of similarly aged women) found that the participants undergoing AI 
treatment reported a significant increase in symptoms from baseline to follow-up that  









included: hot flushes, night sweats, dyspareunia, alopecia, forgetfulness, depression, and 
sleep difficulties (Gallicchio et al., 2011). Women undergoing menopause 
characteristically experience vasomotor symptoms, vaginal atrophy, skeletal, 
psychological, and sexual dysfunctions. With the dramatic fall of estrogen levels in post-
menopausal women, AIs may exacerbate estrogen deprivation that leads to their 
particular symptom profile (Burstein, 2007).   
The most prevalent and troublesome AI reported toxicity is musculoskeletal 
symptoms including arthralgia (Coleman et al., 2008). Crew and colleagues carried out a 
cross-sectional survey of 200 breast cancer patients, where 47% reported AI-related joint 
pain and 44% reported AI-related joint stiffness.  Post-menopausal women often 
experience joint and skeletal pain as part of the natural aging process (Felson & 
Cummings, 2005). Data suggest that joint pains are uniquely associated with AI use with 
47% of patients attributing the cause of their current arthralgia to AI therapy and 74% 
recognized the onset of arthralgia within 3 months of starting treatment (Mao et al., 2009). 
Henry and colleagues (2008) found 44 out of 100 participants in their study qualified for 
referral to rheumatology associated with AI therapy and 13% discontinued AI treatment 
due to rheumatologic toxicity. The areas most commonly affected by AI-related 
arthralgia include in descending order: hands, knees, hips, lower back, and shoulders 
(Donnellan et al., 2001). In the same study, 5% discontinued Anastrozole (third 
generation AI) due to the severity of their symptom and discontinuation lead to the 
resolution of their arthralgia.  
 Variables Associated with AI Symptom Experience. The etiology behind AI 
symptom toxicities is largely unknown and certain variables associated with the 




development of AI-related symptoms have not been clearly established. However, there 
are some data that reported that particular groups had a higher propensity for developing 
AI-related symptoms. Mao and colleagues (2009) performed a cross-sectional survey and 
reported an inverse relationship to the length of time since cessation of menses to onset of 
reported AI-related arthralgia. In a multiple regression analysis, obese participants with a 
BMI between 25 to 30 kg/m2 and participants who received Tamoxifen therapy had an 
inverse relationship with reported AI-joint symptoms (Crew et al., 2007).  
Patients treated with prior taxane chemotherapy were reported to be at a 
significantly higher risk for developing AI-related joint pain and stiffness (Crew et al., 
2007; Henry et al., 2012). Levels of Vitamin D may also be a factor for AI symptom 
emergence with women more likely to report no disability from joint pain who had high 
Vitamin D levels compared to those with lower levels (Khan et al., 2009). Participants 
younger than 55 years of age and those with pre-existing pain at baseline are associated 
with a higher AI discontinuation rate (Henry et al., 2012). 
AI endocrine therapy assists in the depletion of estrogen levels in the body, the 
hormone responsible for ER+ breast cancer to occur. Therefore, it has been hypothesized 
that the adverse effect profile is largely due to estrogen deprivation that drive menopausal 
type symptoms.  Interestingly, Cuzick and colleagues (2008) explored the mechanism 
behind endocrine hormone therapy with related toxicities as a marker for treatment 
efficacy in the ATAC trial (comparison between Anastrozole alone or in combination 
with Tamoxifen). They found that over 30% of women reported vasomotor and joint 
symptoms during the first 3 months of therapy, and subsequently had lower recurrence 
than those who did not report any of these symptoms at 3 months of follow up (Cuzick et 




al., 2008). The results suggest an association between early symptom appearances with 
drug therapeutic effects.  
Although none of these reported findings are absolute predictors associated with 
AI-related symptoms, the efficacy of these drugs to reduce disease recurrence is well 
established and further research to identify these symptoms will help improve clinical 
symptom management.  The purpose of this study is to provide insight into the AI 
symptom profile and explore the severity of reported symptoms in post-menopausal 
breast cancer survivors on AI adjuvant therapy.   
Study Aims 
1. To identify the symptoms of post-menopausal breast cancer survivors currently on 
AI adjuvant therapy who are enrolled in the primary study at the time of 
enrollment. 
2. To describe the severity of the identified symptoms of post-menopausal breast 
cancer survivors currently on AI adjuvant therapy who are enrolled in the primary 
study at the time of enrollment.  
Conceptual and Operational Definition  
 Symptom. A subjective evidence of disease or physical disturbance, broadly: 
something that indicates the presence of bodily disorder. 
The Breast Cancer Prevention Trial Symptom Checklist (BCPT-SCL) (See 
Appendix A) was used to measure this variable. Scores on this Likert-type scale range 
from a 0 (not at all) to a 4 (extremely). The original instrument indicated a response for 
presence of symptom as a yes or no. For this study 0 will indicate no (absence of 
symptom) and severity scores from 1 to 4 will indicate yes (presence of symptom). The 




original instrument was created for the Tamoxifen Prevention Trial (Ganz et al., 1995); 
however, the symptoms assessed are related to menopause and hormonal therapies that 





The primary study is a randomized control trial comparing an endurance-
resistance exercise intervention group to a health promotion control group over a 12-
month period of time. The exercise intervention-experimental group participated in a 
supervised endurance-resistance component 3 times a week, and an additional 
recommended 30-minute aerobic exercise most other days of the week. The health 
promotion control group received recommendations for moderate intensity physical 
activity most days of the week.  
A total of 154 women diagnosed with breast cancer, gynecologic cancers, 
colorectal cancers, and lymphoma were enrolled to examine the effects of an endurance-
resistive exercise intervention on bone mass, body composition, metabolic factors, and 
functional status over time. The goal of the original study was to improve physiological 
health outcomes in an at-risk early post-menopausal cancer survivor population. 
The women were recruited through the Yale–New Haven Hospital and Saint 
Raphael Tumor Registries with HIC approval. Each patient’s physician was contacted to 
request permission to reach out to the patient. Once permission was granted, a letter was 
sent to each woman inviting participation in the study. Recruitment was also done 
through flyers in community practices and in community settings. 




The statistician used a block method to randomly assign participants into the 
exercise intervention group and the health promotion group.  
Sample  
From the 154 women participating in the primary study, 36 women with breast 
cancer were identified who were currently on AI adjuvant endocrine therapy. These 
participants on AI therapy are the focus of the secondary analysis exploring their 
symptom profile at the time of enrollment.  Data were also collected on demographics 
(e.g. age, ethnicity, educational level, employment status, and occupation), and clinical 
variables (e.g. hormone receptor +/-; surgery only; surgery and chemotherapy only; 
surgery and radiation only; surgery and chemotherapy and radiation).  
Data Collection  
In the primary study, patients completed a self-reported Demographic and 
Medical Data Form at baseline before starting the intervention and the Breast Cancer 
Prevention Trial Symptom Checklist (BCPT-SCL). 
Variables 
 Demographic variables.  The following are the demographic variables as self-
reported by participants on the Demographic and Medical Data Form under the 
Demographics section (See Appendix B) in the parent study and the level of 
measurement of each variable. 
 Age. Age in chronological years.  Level of measurement:  interval.  
Ethnicity. Self-reported ethnic identity. Level of measurement:  nominal.  
 Education level. High School Graduate; Trade or Technical School; Some 
College; College Graduate; Graduate School. Level of measurement:  ordinal. 




 Employment status. Full-time; Part-time; Retired; Temporarily not Employed. 
Level of measurement: nominal.   
 Clinical variables.  The following are the clinical variables as self-reported by 
participants on the Demographic and Medical Data Form under the Cancer/Medical Data 
section (See Appendix B) in the parent study and the level of measurement of each 
variable.  
 Hormone receptor. Estrogen receptor positive or negative; Progesterone receptor 
positive or negative; Her-2/neu positive or negative. Level of measurement: nominal. 
 Primary treatment types. Surgery only; surgery and chemotherapy only; surgery 
and radiation only; surgery and chemotherapy and radiation. Level of measurement:  
nominal. 
 Number of symptoms.  As reported by the BCPT-SCL.  For Study Aim 1, we 
used each item of the 42 items of the BCPT-SCL individually. Level of measurement:  
interval.  
 Severity of symptoms.  As reported by the BCPT-SCL. For Study Aim 2, the 
mean severity scores are calculated for each reported symptom (range = 1-4).  The higher 
the number, the more severe that particular symptom experience is to the participants 
reported. Level of measurement: interval. 
Data Analysis  
Sample. The demographic and clinical characteristics of the sample were 
described using frequencies and measures of central tendency and dispersion, depending 
on the level of measurement of the variable.  




 Study Aim 1. Each of the 42 items on the BCPT-SCL was described using 
frequencies of those who reported having the symptom and measures of central tendency 
and dispersion for each item of the BCPT-SCL.  
 Study Aim 2. Of the 42 items identified on the BCPT-SCL, we used the mean 
value to describe the severity of each symptom identified.  
Ethical Considerations 
 Permission to conduct this study was obtained by the parent study through the 
Yale University Human Investigations Committee, protocol number 0801003383, granted 




 The demographic and clinical characteristics were analyzed with the descriptive 
statistics package of SAS v 9.2. The demographic characteristics are described in Table 2. 
The average age was 57.9 years (SD 7.09, range = 39-75); ethnicity was mostly white 
(86.5%), the majority had a graduate degree (36.1%), and almost half worked full time 
(51.4%). 
 
Table 2. Demographic characteristics of subjects (N=36)  
Characteristics           Mean SD  Frequency (%)  
 
Age (years)                           58           7.14     
Ethnicity          
White      32   (88.8) 
Black or African       2   (5.6) 
Other        2   (5.6) 
Education level          
High school/ trade school      6   (17.1)                   
Some college        8   (22.9)  
College graduate       9   (25.7) 
Graduate school      12  (34.3) 
Employment status         
 Full-time       18  (50) 
 Part-time        8   (22.2) 
 Retired        6   (16.7) 
 Temp employed       4   (11.1) 





 The medical characteristics are represented in Table 3. All participants on AI 
therapy were estrogen receptor (ER) positive, while only 7.1% of participants were Her-
2/neu (HER2) positive. The majority of women had breast conservation therapy with 
radiation therapy as part of their treatment. Almost one-third (30.6%) had complete 
mastectomies and a quarter of the women did not receive radiation treatment. Nearly half 
(52.8%) of the women received adjuvant chemotherapy and 47.2% did not.  
 
Symptom Profile 
 Of the 42 symptoms from the BCPT-SCL, the symptoms reported by ≥ 30% of 
participants and their mean severity scores are depicted in Table 4. The most frequently 
reported symptoms were joint pain (75%), hot flashes (75%), and general aches and pains 
(75%) followed by muscle stiffness (69.4%), unhappy with appearance (61.1%), breast 
sensitivity (61.1%), forgetfulness (61.1%), night sweats (58.3%), vaginal dryness 
(58.3%), and headaches (52.8%).  
The highest reported mean severity score was unhappiness with body image (2.2) 
and the next top most frequently reported symptoms reflected mild to moderate mean 
severity distress scores were hot flashes (1.9), breast sensitivity (1.8), night sweats (1.8), 
joint pain (1.7), early awakening (1.7), forgetfulness (1.6), general aches and pains (1.5), 
Table 3. Medical characteristics of subjects (N=36)  
Characteristics           ____   Frequency (%)  
 
Hormone Receptor          
Estrogen receptor +            28 (100) 
Progesterone receptor +           23 (82.1) 
Her-2/neu +               2 (7.1)     
Surgery         
Breast Conservation            25 (69.4) 
Mastectomy               11 (30.6)             
Radiation         
 Yes              27 (75) 
No                9 (25) 
Adjuvant Chemotherapy 
Yes              19 (52.8) 
No              17 (47.2) 




difficulty concentrating (1.5), pain with intercourse (1.5), social avoidance (1.5), short 
temper (1.5), and tendency to take naps (1.5). 
The remaining 20 of 42 symptoms that were under the range were reported only 
by 8.1%-27% of participants and were associated with minimal symptom distress (mean 












Table 4. Symptoms Reported by ! 30% of Participants and Mean Severity Scores* 
Symptom  n (%) who reported 1-4  Mean Severity Score*        SD 
   (presence of symptoms)  range 1-4 (to the nearest 
       tenths) 




Breast sensitivity  




































Tendency to take naps 
Pain with intercourse 
Diarrhea 





































Constipation 11 (30.6) 1.1 0.70 
* Mean severity rated from 1 (mild to slight distress); 2 (moderate); 3 (quite a bit); 4 (extremely) 






 Post-menopausal breast cancer survivors who are hormone receptor positive are 
often put on adjuvant AI therapy that may have lasting toxicities effecting quality of life, 
as well as adherence to therapy. Previous literature has shown that the most prevalent and 
troublesome symptom experienced by patients on AIs were musculoskeletal in nature, 
especially arthralgia (Coleman et al., 2008). AI therapy may also exacerbate menopausal 
effects such as vasomotor symptoms related to further estrogen deprivation (Burstein, 
2007). This study found similar results to Coleman and colleagues (2008) and Burstein’s 
(2007) studies where the most frequently reported symptom of the study population was 
joint pain (n = 27), hot flashes (n = 27), and general aches and pains (n = 27).   
 Interestingly the highest reported severity score in this study was related to body 
image due to unhappiness with their body’s appearance. Ganz and colleagues (2003) 
conducted a cohort study of 577 breast cancer survivors who were disease-free for a 
minimum of 2 years. They found that emotional distress was higher in younger women 
undergoing menopausal transition related to therapy. They also found one of the most 
prevalent complaints was being unhappy with their body at breast cancer diagnosis 
among all ages (range 25-51), and were not age group specific (Ganz et al., 2003). Of the 
577 women in the study, 55.8% underwent a lumpectomy, 44.2% underwent a 
mastectomy, and the majority did not choose reconstruction surgery (Ganz et al., 2003).  
In another study done by Ganz and colleagues (2004), breast cancer patients who 
received lumpectomy surgery without chemotherapy had the lowest reported rate of 
being unhappy with appearance (Ganz et al., 2004). One study found that concerns with 




appearance correlating with weight gain had higher weight/appearance scale scores in 
women who had been treated with chemotherapy (Alfano et al., 2006). Emotional distress 
relating to body image in breast cancer patients can vary widely throughout their 
treatment course with possible factors including diagnosis of breast cancer, primary 
treatment, reconstruction, and adjuvant therapy that may effect their overall quality of life 
after completion of treatment.  
In a recent study that looked at the effects of an exercise intervention on 
symptoms in breast cancer survivors, 62% of the sample were on endocrine therapy with 
hot flashes, joint pains, and muscle stiffness as the most reported symptoms (Knobf et al., 
2013). Alfano and colleagues (2006) study, using a shortened version of the BCPT 
Symptom Checklist, found that 98% of their breast cancer population reported hormone-
related symptom in the past year and the women who predominantly reported vasomotor 
symptoms had received chemotherapy treatment, Tamoxifen therapy, and were post-
menopausal.  
The findings of this study confirm the most prevalent distressing symptoms 
include musculoskeletal and vasomotor symptoms in breast cancer survivors on AI 
therapy. 
Limitations of the Study 
Limitations of this study include a small sample size and homogenous group of 
women. A larger sample size with a more heterogeneous group of women would increase 
reliability of observations. Other limitations include unknown time of diagnosis, 
unknown time of AI treatment initiation, and varying lengths of AI treatment times 
before starting the study.  




Implications for Research 
 Further studies would benefit in exploring the association of symptoms and 
severity of symptoms with demographic and clinical variables reported by these breast 
cancer survivors on AI adjuvant therapy. The new results from the ATLAS trial 
comparing 5 years of adjuvant Tamoxifen versus 10 years has suggested that the latter 
can further decrease breast cancer recurrence and mortality in half (Davies et al., 2012). 
There is no current evidence that extended AI therapy past 5 years have similar effects to 
the results from the ATLAS trial. Previous studies have shown that Letrozole (third 
generation AI) may show greater benefit in patients with hormone positive tumors 
compared to Tamoxifen (Gross et al., 2007). Data suggests that using an AI for upfront 
monotherapy, sequential therapy 2 -3 years after Tamoxifen, or extended therapy after 5 
years of Tamoxifen reduced the recurrence of breast cancer compared to Tamoxifen for 5 
years alone (Burstein et al., 2010). Future research with randomized clinical trials will 
give more insight on the efficacy of AIs used in extended therapy.   
Implications for Practice 
There is no confirmed etiology behind AI musculoskeletal symptoms, and 
evidence-based management for musculoskeletal complaints related to AI therapy have 
yet to be established. A thorough history and physical assessment of each patient will 
provide better insight in clinical management. A complete musculoskeletal assessment 
with consideration of NSAID or acetaminophen administration can help provide the best 
individualized care for patients (Park, Knobf, & Sutton, 2012).  The efficacy of AIs to 
reduce recurrence of disease and mortality in breast cancer survivors emphasize the 
importance for future studies to assist in identifying AI-related symptom toxicities, 




establishing management techniques, and minimizing symptom distress to improve 
adherence to AI therapy. Prospective studies identifying the critical symptoms and their 
associated variables responsible for decreasing quality of life in breast cancer survivors 
on AI therapy will help improve the clinical decision-making model to maximize 
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